NASDAQ:QTTB

Q32 Bio (QTTB) Stock Price, News & Analysis

Q32 Bio logo
$8.36 -0.12 (-1.36%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$8.35 -0.02 (-0.18%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Q32 Bio Stock (NASDAQ:QTTB)

Advanced

Key Stats

Today's Range
$8.22
▼
$8.59
50-Day Range
$7.52
▼
$11.17
52-Week Range
$1.93
▼
$23.57
Volume
476,717 shs
Average Volume
360,355 shs
Market Capitalization
$250.28 million
P/E Ratio
2.50
Dividend Yield
N/A
Price Target
$32.17
Consensus Rating
Moderate Buy

Company Overview

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms.

The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Q32 Bio became a publicly traded company in 2024 through a business combination with Homology Medicines. The combined company retained the Q32 Bio name and trades on the Nasdaq under the symbol QTTB.

AI Generated. May Contain Errors.

Q32 Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

QTTB MarketRank™: 
3.70478170478 of 5 stars

Q32 Bio scored higher than 74% of companies evaluated by MarketBeat, and ranked 139th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Q32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Q32 Bio has a consensus price target of $32.17, representing about 284.5% upside from its current price of $8.37.

  • Amount of Analyst Coverage

    Q32 Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Q32 Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Q32 Bio are expected to decrease in the coming year, from ($1.42) to ($1.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Q32 Bio is 2.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.27.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Q32 Bio is 2.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.60.

  • Price to Book Value per Share Ratio

    Q32 Bio has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    28.50% of the float of Q32 Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Q32 Bio has a short interest ratio ("days to cover") of 12.13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Q32 Bio has recently decreased by 1.10%, indicating that investor sentiment is improving.
  • Dividend Yield

    Q32 Bio does not currently pay a dividend.

  • Dividend Growth

    Q32 Bio does not have a long track record of dividend growth.

  • News Sentiment

    Q32 Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Q32 Bio this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $320,397.00 in company stock.

  • Percentage Held by Insiders

    34.46% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    31.32% of the stock of Q32 Bio is held by institutions.

  • Read more about Q32 Bio's insider trading history.
Receive QTTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QTTB Stock News Headlines

Q32 Bio Inc. (QTTB) - What Are Analysts Thinking About This Stock?
Head-To-Head Review: Q32 Bio (QTTB) versus Its Competitors
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
Jefferies Keeps Their Buy Rating on Q32 Bio (QTTB)
See More Headlines

QTTB Stock Analysis - Frequently Asked Questions

Q32 Bio's stock was trading at $3.32 on January 1st, 2026. Since then, QTTB shares have increased by 152.0% and is now trading at $8.3650.

Q32 Bio Inc. (NASDAQ:QTTB) announced its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07.

Q32 Bio (QTTB) raised $135 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share.

Top institutional investors of Q32 Bio include American Century Companies Inc. (2.18%), Baker BROS. Advisors LP (1.83%), Marshall Wace LLP (1.23%) and Goldman Sachs Group Inc. (0.96%). Insiders that own company stock include Orbimed Advisors Llc, Diyong Xu, Jodie Pope Morrison, Lee Kalowski, Shelia M Violette and Paul Alloway.
View institutional ownership trends
.

Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Broadcom (AVGO), Cameco (CCJ), Pfizer (PFE), Barrick Mining (B) and BigBear.ai (BBAI).

Company Calendar

Last Earnings
11/04/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:QTTB
Previous Symbol
NASDAQ:QTTB
CIK
1661998
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

High Price Target
$40.00
Low Price Target
$14.00
Potential Upside/Downside
+284.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.34
Trailing P/E Ratio
2.50
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$29.82 million
Net Margins
N/A
Pretax Margin
60.02%
Return on Equity
17.03%
Return on Assets
15.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
56.34
Quick Ratio
56.34

Sales & Book Value

Annual Sales
$53.74 million
Price / Sales
4.66
Cash Flow
$1.53 per share
Price / Cash Flow
5.47
Book Value
$9.61 per share
Price / Book
0.87

Miscellaneous

Outstanding Shares
29,920,000
Free Float
19,612,000
Market Cap
$250.28 million
Optionable
Optionable
Beta
0.45
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:QTTB) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners